Impairment in gut epithelial integrity and barrier function is associated with many diseases. The homeostasis of intestinal barrier is based on a delicate regulation of epithelial proliferation and differentiation. AMP-activated protein kinase (AMPK) is a master regulator of energy metabolism, and cellular metabolites are intrinsically involved in epigenetic modifications governing cell differentiation. We aimed to evaluate the regulatory role of AMPK on intestinal epithelial development and barrier function. In this study, AMPK activator (AICAR) improved the barrier function of Caco-2 cells as indicated by increased transepithelial electrical resistance and reduced paracellular FITC-dextran permeability; consistently, AICAR enhanced epithelial differentiation and tight junction formation. Transfection of Caco-2 cells with AMPK WT plasmid, which enhances AMPK activity, improved epithelial barrier function and epithelial differentiation, while K45R (AMPK dominant negative mutant) impaired; these changes were correlated with the expression of caudal type homeobox 2 (CDX2), the key transcription factor committing cells to intestinal epithelial lineage. CDX2 deficiency abolished intestinal differentiation promoted by AMPK activation. Mechanistically, AMPK inactivation was associated with polycomb repressive complex 2 regulated enrichment of H3K27me3, the inhibitory histone modification, and lysine-specific histone demethylase-1-mediated reduction of H3K4me3, a permissive histone modification. Those histone modifications provide a mechanistic link between AMPK and CDX2 expression. Consistently, epithelial AMPK knockout in vivo reduced CDX2 expression, impaired intestinal barrier function, integrity and ultrastructure of tight junction, and epithelial cell migration, promoted intestinal proliferation and exaggerated dextran sulfate sodium-induced colitis. In summary, AMPK enhances intestinal barrier function and epithelial differentiation via promoting CDX2 expression, which is partially mediated by altered histone modifications in the Cdx2 promoter.
Intestinal epithelium is responsible for nutrient absorption and defense against harmful microorganisms and lumen contents. 1 Impaired intestinal barrier function is one of the key etiological factors of inflammatory bowel disease (IBD), and other digestive tract diseases. 2 Thus, proper intestinal barrier is essential for health, which requires a delicate regulation of epithelial proliferation and differentiation. 1 Adenosine monophosphate-activated protein kinase (AMPK) is a heterotrimer; the catalytic α-subunit of AMPK has two isoforms. 3 AMPK is a master regulator of energy metabolism, and its inactivation was recently discovered as a major etiological factor of many diseases, including obesity and diabetes. 4 Because diabetic and obese mice showed leaky intestinal barrier features, 5 AMPK inhibition due to these conditions may be a key contributor to the impaired gut epithelial differentiation and barrier function. Consistently, the microbial metabolite, butyrate, enhances barrier function and alleviates metabolic syndrome through activation of AMPK. 6 In addition, AMPK is involved in the establishment and maintenance of intestinal polarity and localization of glucose transporters. 7 Up to now, however, the role of AMPK in intestinal epithelial differentiation and colitis onset has not been studied.
Caudal type homeobox 2 (CDX2) is a key transcription factor governing differentiation of intestinal epithelial cells. 8 Epigenetic modifications are indispensable for transcription initiation, which loosen chromatin structure and allow the binding of RNA polymerase to initiate transcription. 9 Polycomb repressive complex 2 (PRC2), containing the enhancer of zeste homolog 2 (EZH2) catalytic subunit, trimethylates H3K27 (H3K27me3) to silence the transcription of target genes. 10 Lysine-specific histone demethylase-1 (LSD1) and lysine demethylase 5 remove H3K4 trimethylation (H3K4me3) to inhibit gene transcription. 11 The co-existence of H3K27me3 and H3K4me3 in key developmental genes to forms a 'bivalent state', which poses the gene to express via enriching H3K4me3 and reducing H3K27me3, 12 though the bivalent state of Cdx2 gene has not been studied. Recent studies suggest an intrinsic link between metabolism and epigenetic modifications. 13 Drugs altering AMPK activity change histone modifications in J1 ES cells 14 and HepG2 cells. 15 These data prompted us to hypothesize that AMPK promotes epithelial differentiation and enhances epithelial barrier function via epigenetically promoting Cdx2 expression. Sucrase-isomaltase (SI), E-cadherin, dipeptidyl peptidase-4 (DPPIV) and villin protein levels as well as alkaline phosphatase (AP) activity were increased in response to (Figures 1a and b) . However, 0.5 mM AICAR did not change AP activity at 4 days and even decreased its activity after 7 days (Figure 1a) . Even though the mechanisms were not understood, as a AMP analog, a high level of AICAR might mimic starvation, which induces a rapid decrease in the expression of intestinal AP, while refeeding resulted in AP upregulation. 16 Associated with AMPK activation and enhanced epithelial differentiation, the epithelial barrier function was improved as shown by increased transepithelial electrical resistance (TEER; Figure 1c ) and decreased paracellular permeability of FITCdextran ( Figure 1d ). To assess the reassembly of calciuminduced tight junction, we monitored the relocation of ZO-1 after switching to calcium containing medium. The assembly ability of tight junction in response to calcium switch ( Figure 1e ) was greatly enhanced by 0.2 mM AICAR treatment. Given that cellular responses to 4 and 7 days of AICAR treatments were similar, 0.2 mM AICAR treatment for 4 days was used in subsequent studies.
Because AICAR is regarded as a nonspecific activator of AMPK due to its ability to activate AMP-dependent enzymes, 17 Caco-2 cells were further transfected with AMPKα AMPK promotes intestinal epithelial differentiation through upregulating CDX2 expression. CDX2 is the key transcription factor governing epithelial cell differentiation. 8 In response to 0.2 mM AICAR treatment, CDX2 protein content increased after 48 h (Figure 3a ). Consistently, Cdx2 mRNA level was enhanced at 24 h of treatment (Figure 3b ). The slightly delayed increase in CDX2 protein content compared to its mRNA expression could be due to the time needed for protein synthesis and post-translational modifications. 18 Immunofluorescence staining revealed a lower level of CDX2 expression in Caco-2 cells with kinase dead K45R plasmid compared to Caco-2 cells with AMPK WT plasmid (Figures 3c and d) .
To further examine the mediatory role of CDX2 in linking AMPK to epithelial differentiation, we used CRISPR/Cas9 system to knockout CDX2. CRISPR/Cas9 system itself showed no effect on Caco-2 cells as indicated by the predicted selectivity of sgRNA (Supplementary Figure S1a and b) , and no change in the expression of CDX2 and differentiation markers in cells transfected with scrambled CRISPR/Cas9 plasmid (Supplementary Figure S1c) , while CDX2 expression was decreased greatly after CDX2 specific CRISPR/Cas9 transfection and sorting (Figure 4b ). 0.2 mM AICAR activated AMPK both in CDX2 control (Scramble-sgRNA) and CDX2 knockout (Cdx2 sgRNA) cells (Figure 4a ). Consistently, CDX2 knockout abolished epithelial differentiation enhanced by AICAR as indicated by unchanged AP activity as well as E-cadherin and villin contents in response to AICAR treatment (Figures 4b and c) , clearly showing that AMPK-enhanced epithelial differentiation through enhancing CDX2 expression.
AMPK regulates Cdx2 expression through inducing histone modifications. To assess whether the enhanced CDX2 level observed in epithelial cells with AMPK stimulation was due to epigenetic alterations in the Cdx2 promoter, we further analyzed permissive histone modification H3K4me3 and inhibitory histone modification H3K27me3 based on NCBI ChIP-seq profiles of the Cdx2 promoter (Figure 5a ). H3K4me3 and H3K27me3 are abundant in the Cdx2 promoter, making it into a bivalent state, which keeps the gene in a poised status. We further analyzed the abundance of CpG islands in the Cdx2 promoter. As expected, exceptionally rich CpG sites in the Cdx2 promoter were found (Figure 5b ), consistent with the characteristics of bivalent key developmental genes. To test whether AMPK alters the bivalent state of Cdx2 promoter to regulate its expression, we further used chromatin immunoprecipitation (ChIP) of H3K4me3 and H3K27me3 followed by PCR using primers specific to the Cdx2 promoter. AMPK deletion in vivo dramatically decreased H3K4me3 and increased H3K27me3 contents ( Figure 5c ). In vitro, AICAR treatment increased H3K4me3 but not H3K27me3 in the promoter of Cdx2 gene (Figure 5d ). In alignment, H3K4me3 was enriched while H3K27me3 was reduced in cells transfected with AMPKα WT plasmid compared to those with kinase dead K45R plasmid ( Figure 5e ). PRC2 bears histone methyltransferase activity on H3K27me3, while LSD1 is a histone demethylase for H3K4me1/2. To further explore the underlying mechanism, EZH2 and LSD1 binding to the Cdx2 promoter were analyzed by ChIP. Consistent with reduced H3K4me3 and enriched H3K27me3, EZH2 and LSD1 were recruited to the Cdx2 promoter after AMPK knock out (Figures 5c and e). These data indicated that AMPK regulates Cdx2 expression at least partially through inducing histone modifications by recruiting methylase PRC2 and demethylase LSD1 to the Cdx2 promoter (Figure 5f ).
AMPK deletion reduces CDX2 expression, impairs barrier function and exacerbates colitis in vivo. To assess the regulatory role of AMPK in intestinal epithelium in vivo, we cross-bred AMPKα1-floxed mice with VilCre mice to specifically knock out AMPKα1 gene in intestinal epithelial cells where villin is expressed. AMPK was efficiently deleted in the gut epithelium of AMPK VilCre mice, as indicated by immunofluorescence staining (Figure 6a ) and dramatically decreased phospho-AMPK and AMPKα1 ratio (Figure 6b ). We further examined the expression pattern of CDX2 in WT and AMPK VilCre mice. CDX2 in WT mice resided along the epithelial cells from crypts to the most of villi, whereas CDX2 in AMPK VilCre extended from crypt to the middle of villi (Figures 7a and b) . Consistently, the protein content of CDX2 was reduced in AMPK VilCre mice (Figure 7c) . Consequently, the brush border enzyme, SI and DPPIV, were abated in AMPK VilCre mice (Figure 7d) . Similarly, the contents of intestinal junctions, such as ZO-1 and E-cadherin, and villin were diminished (Figure 7e ). To investigate the integrity of tight junctions, ZO-1 immunofluorescence staining was analyzed. The pattern of ZO-1 at the tip of villi was impaired in jejunum tissue of AMPK Vilcre mice (Figure 7f ), which was in alignment with CDX2 pattern (Figure 7a ). To examine the ultrastructure of tight junctions, transmission electron microscopy (TEM) was further conducted. The intercellular tight junctions appeared to be denser in WT mice than that in AMPK VilCre mice (Figure 7g) .
To demonstrate the clinical importance, we next examined colitis susceptibility of these mice upon dextran sulfate sodium (DSS) induction. Epithelial specific AMPK deletion in mice resulted in increased disease activity index (DAI) scores, watery and bloody diarrhea, and dramatic body weight loss in response to DSS challenge (Figure 8a ). Furthermore, AMPK VilCre mice had significantly higher histopathological scores compared to WT mice (Figure 8b ), suggesting AMPK deletion exacerbated colitis. In addition, AMPK mice display mortality during colitis induction; one mouse was died in AMPK VilCre group during DSS treatment while all mice in WT group survived DSS challenge.
Discussion
Gut epithelium forms the largest and critical barrier against the external environment, which is constantly renewed. 19 During intestinal epithelial development, enterocytes migrate from the crypt base to villi while differentiate into enterocytes, goblet cells and enteroendocrine cells. 20 The balance of epithelial proliferation, differentiation and migration is critical for epithelial health. 21 Impairment in gut epithelial integrity and barrier function, so called 'leaky gut' is a central etiological factor for IBD. In this study, AMPK villin specific deletion deteriorated DSS-induced colitis, indicating AMPK might be a key mediator involved in the etiology of IBD. Similarly, the administration of AMPK activator, AICAR, attenuated 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced acute and relapsing colitis. 22 This ameliorative effects of AMPK on IBD likely result from improved epithelial barrier function. Besides in IBD, abnormal intestinal barrier function was one of the key causes of metabolic disorders. Disrupted epithelial barrier function is associated with obesity and diabetes. 23 In addition, a number of diseases and pathophysiological states such as obesity caused by high fat diet and sedentary life style are associated with attenuation of AMPK activity; 24 AMPK activation by AICAR or exercise mitigates symptoms associated with these conditions. 4 Metformin, a most commonly used therapeutic drug for diabetes and obesity, activates AMPK, having beneficial effects on fructose-induced loss of tight junction in duodenum. 25 Using IL-10 KO mice, we found that metformin supplementation improved intestinal epithelial barrier function associated with enhanced AMPK activation in ileum. 26 Therefore, AMPK exhibits crucial roles in mitigating IBD, and metabolic disorders-induced bowel dysfunctions, which might be partially caused by abnormal intestinal barrier function. However, the underlying connection and crosstalk between metabolic sensor and intestinal barrier function have only been sparsely studied. This study examined the role of AMPK in mediating intestinal epithelial barrier function and further explored underlying mechanisms.
AMPK contains one catalytic α-subunit, which has two isoforms, α1 and α2. AMPK α1 is mainly expressed in intestinal epithelial cells, 27 thus its role in epithelial differentiation was examined in the current study. As an important regulator of energy metabolism, AMPK activation or inhibition due to chemicals or pathophysiological states results in complicate changes in the whole body. To clearly define the role of AMPK in epithelial differentiation, we specifically knocked out AMPKα1 gene in epithelial cells expressing villin in vivo. Deletion of AMPK in epithelial cells augmented in vivo intestinal permeability. This is consistent with a previous study showing AMPK inactivation in obese mice was associated with barrier dysfunction. 28 However, in IL-10 KO mice, where severe inflammation occurs due to the absence of a key antiinflammatory cytokine, AMPK activation was associated with impairment of gut epithelial barrier function. 29 Such AMPK activation could be due to the impairment in energetic metabolism elicited by inflammation. 30 Caco-2 cells differentiate after confluence, resembling epithelial differentiation in vivo, which have been widely used for studying intestinal barrier function in vitro.
6 AICAR, the AMPK activator, can be transported into cells and converted into AMP analog. 31 AICAR promotes TEER in MDCK cells and Caco-2 cells, 32 while compound C that inhibits AMPK activity abolishes intestinal barrier function. 6 Consistent with previous reports, AICAR treatment enhances barrier function and epithelial differentiation in Caco-2 cells. ZO-1 is a critical component of the tight junction complex. 33 In line with improved barrier function, AICAR accelerates the assembly of tight junction. In support, butyrate, which activates AMPK, promotes ZO-1 re-localization and tightens intestinal barrier. 6 These studies demonstrate the regulatory role of AMPK on epithelial differentiation and barrier function. However, in addition to activate AMPK, AICAR also activates other AMPdependent enzymes, which may complicate interpretation of results. 17 To avoid these complications, Caco-2 cells were further transfected with AMPK WT and kinase dead K45R plasmids. Consistently, Caco-2 cells transfected with AMPK WT plasmid had enhanced epithelial differentiation, tight junction assembly and improved barrier function, while cells with AMPK kinase dead K45R plasmid had opposite phenomena. Of note, the TEER of AMPK K45R gradually caught up with that of control Caco-2 cells transfected with GFP over time, which was likely due to gradual loss of transfected plasmids in cultured cells. These data in combination clearly show that AMPK is an effective pharmacological target for enhancing intestinal epithelial differentiation and barrier function.
CDX2 is the key transcription factor regulating epithelial differentiation, which primarily expresses in less differentiated epithelial cells. 34 A previous study showed that CDX2 expression presented a vertical gradient with less expression at the tips of the villi. 34 CDX2 overexpression promotes differentiation of HT-29 cells and IEC-6 cells, 35 while CDX2 deficiency impairs enterocyte apical/basolateral polarity and morphogenesis. 36 In the jejunum of AMPK VilCre mice, we found that CDX2 was limited to the lower and mid-villi, which may lead to reduced mucosal height, migration ability and tight junction formation. We further found that CDX2 expression was greatly enhanced in Caco-2 cells with enhanced AMPK activity, which was associated with improved barrier function and differentiation, while CDX2 deletion inhibited epithelial differentiation. In support of our observations, AICAR promotes CDX2 activity in mammalian embryonic development, while compound C inhibits. 37 These data show that AICAR promotes intestinal differentiation directly via upregulation of CDX2. On the other hand, CDX2 is considered as a tumor suppressor, 38 playing a crucial role in inhibiting proliferation. 39 We found proliferation was enhanced in AMPK VilCre mice, which might be partially through inhibiting CDX2. In support, the cell proliferation and cyclin D1 expression were decreased after CDX2 is induced in human intestinal epithelial crypt (HIEC) cells. 40 Histone modifications regulate gene expression. As a key developmental gene, the promoter of Cdx2 is enriched with both H3K27me3 and H3K4me3, forming a 'bivalent state'. 41 Our data showed that AMPK activation facilitates permissive H3K4me3 and impedes inhibitory H3K27me3 modification in the Cdx2 promoter, explaining the enhanced Cdx2 expression due to AMPK activation. Furthermore, EZH2, the enzymatic component of PRC2, is one of PcG proteins that catalyzes trimethylation of H3K27. 42 In embryonic stem cells, PRC2 works with PRC1 to repress the Cdx2 expression. 43 LSD1 is the demethylase for H3K4me1/2. 44 In trophoblast stem cells, deletion of LSD1 in mice promotes the expression of Cdx2. 45 In agreement with its functionalities and decreased Cdx2 expression in AMPK WT transfected cells, the deletion of AMPK led to increased EZH2 and LSD1 recruitment in the Cdx2 promoter.
In summary, for the first time, we found that AMPK strengthens intestinal barrier function and intestinal differentiation through enhancing the expression of Cdx2, which is associated with the enhanced formation of permissive histone modification in the Cdx2 promoter, and decreased binding of PRC2 and LSD1 to the Cdx2 promoter. In vivo mice study demonstrated that AMPK deficiency in intestinal epithelial resulted in exaggerated DSS-induced colitis, a commonly used IBD model. These data deepen the current understanding about the link between the intracellular energy sensor, AMPK and intestinal epithelial differentiation. Our finding is important because AMPK activity is altered due to a number of pathophysiological conditions such as obesity, diabetes and inflammation, which is known to impair epithelial barrier function. Thus, AMPK provides an ideal drug target for improving gut epithelial health. The translational value of our finding is highlighted by the wide availability of drugs activating AMPK such as the popular antidiabetic drug, metformin, which can be used to improve gut epithelial health.
Materials and Methods
Mice strains. C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Mice with AMPKα1-floxed gene (Prkaa1 tm1.1Sjm /J, Stock#: 014141, Jackson Lab) were cross-bred with VilCre mice (B6.Cg-Tg Vil-cre 997Gum /J, Stock#: 004586, Jackson Lab) to obtain AMPKα1 villin specific KO (AMPK VilCre) mice. Eight AMPK VilCre male mice and eight wild type (WT) male mice were killed at two and half months of age for epithelial permeability and epithelial cell migration assays. In addition, eight AMPK VilCre and eight WT mice were euthanized at two and half months of age for proliferation assays. Five AMPK VilCre male mice and five WT male mice were killed at three and half months of age for DSS-induced colitis. All studies were performed in an approved protocol by the Institutional Animal Care and Use Committee (IACUC) at Washington State University.
In vivo permeability, migration and proliferation assays. Intestinal permeability to FITC-dextran 40 in vivo was carried out as previously described with modifications. 46 Briefly, mice were fasted for five hours and orally gavaged with 500 mg/kg body weight FITC-dextran (Sigma, St. Louis, MO, USA). Serum was collected 4 h after gavage and diluted 1:5 with PBS, pH7.4. The fluorescent intensity of each sample was measured on the Synergy H1 microplate fluorescence reader (BioTek, Winooski, VT, USA).
To assess epithelial migration, mice were injected with 100 μl of BrdU (10 mg/ml in saline, i.p.) (BD Pharmingen, San Jose, CA, USA) at 24 h prior to sacrifice. 47 To assess epithelial proliferation, another set of mice were injected with BrdU at 2 h prior to sacrifice. At necropsy, a small section of jejunum tissues was frozen in OCT medium for cryo-section preparation and immunostaining. For migration, the distance of foremost BrdU-positive cells to the bottom of crypts indicates the extent of epithelial migration. The mucosal height was measured from crypt base to villus tip. Five sections per mouse were assessed in a blind manner. For proliferation, the percentage of BrdU-positive cells relative to total cell number per crypt was quantified. Three crypts per section, and three sections per mouse were assessed in a blind fashion.
DSS-induced colitis. Colitis was induced by 3% (w/v) dextran sulfate sodium (DSS, Millipore Corporation, Billerica, MA, USA) in drinking water for 6 days, and followed by a recovery period of 6 days. The disease activity index (DAI) scores including body weight, gross bleeding and stool consistency were monitored daily. 48 Each parameter of DAI was scored from 0 to 4. The body weight was scored as 0, 1, 2, 3 and 4 when weight loss was o1%, 1-5%, 5-10%, 10-20% and 420%, respectively. The gross bleeding was scored as 0, 1, 2, 3 and 4 when there was no bleeding, no visible blood but stool color changed, small area visible blood, large area visible blood and gross blood on most stool. The stool consistency was scored as 0, 1, 2, 3 and 4 when the stool was firm, soft but could pick up, could not pick up but had shape, could not pick up without shape and watery, respectively.
Cell culture. Caco-2 cell line was purchased from American Type Culture Collection (Manassas, VA, USA) and grown at 37°C with 5% CO 2 in a humidified incubator in DMEM (Sigma) supplemented with 10% fetal bovine serum (GE, Fairfield, CT, USA) and 1% penicillin-streptomycin (Life Technologies, Grand Island, NY, USA). Unless specified, the medium was refreshed every 48 h.
For AICAR treatment, Caco-2 cells were seeded at a density of 2 × 10 5 per well on 12-well plates, and treated with 0, 0.2 or 0.5 mM of 5-aminoimidazole-4-carboxamide riboside (AICAR; Toronto Research Chemical Inc., Ontario, Canada) for 0, 12, 24, 48, and 96 h (for immunoblotting assay and mRNA assay) as well as 4 days (for alkaline phosphatase assay, immunoblotting assay and immunofluorescent staining), 7 days (for alkaline phosphatase assay) and 21 days (for in vitro barrier function assessment). Medium was refreshed every day.
For plasmid transfection, Caco-2 cells were transfected with plasmids using Lipofectamine 3000 (Life Technologies) per manufacturer's instructions. Caco-2 cells at 70% confluence were transfected with plasmid constructs containing pAMPKα WT (WT), pAMPKα K45R mutant (K45R), and green fluorescent protein (GFP; CON; Catalog no. 15991, 15992 and 13031; Addgene, Cambridge, MA, USA) using a 2 : 4 : 4 ratio of DNA (μg): lipofectamine (μl): lipofectamine 3000 (μl). Medium was changed 12 h post transfection, when 400 μg/ml G418 (Amresco, Solon, OH, USA) was added to the transfected cells for 7 days to enrich cells with transfection. Then the transfected cells were seeded onto 12-well plates at 2 × 10 5 cells per well for 4 days (for alkaline phosphatase assay and immunoblotting assay), 7 days (for alkaline phosphatase assay) and 21 days (for in vitro barrier function assessment). Medium was refreshed every day.
The pX330 CRISPR/Cas9 plasmids with Cdx2 sgRNA (CDX2 knockout) and corresponding random sequences (Scramble-sgRNA) were designed and purchased from Genescript (Piscataway, NJ, USA). Caco-2 cells were transfected with a Cdx2 sgRNA plasmid or a Scramble-sgRNA plasmid. Three days later, transfected cells with GFP expression (plasmid carries GFP gene) were isolated using FACSAria (BD bioscience, San Jose, CA, USA). Sorted cells were cultured in plates, then seeded onto 12-well plates at 2 × 10 5 cells per well, and treated with 0.2 mM AICAR for 4 days. Medium was refreshed every day.
Alkaline phosphatase assay. Alkaline phosphatase (AP) assay was performed as previously described. 16 Briefly, Caco-2 cells were seeded onto 12-well plates at 2 × 10 5 cells per well for 4 days or 7 days, rinsed with PBS, lysed and collected for AP activity measurement. Alkaline phosphatase was assayed by incubating with substrate, pNPP (Sigma), at 37°C for 30 min. The reaction was stopped with 3 mM NaOH. The absorbance at 405 nm was measured using Synergy H1 microplate reader.
Immunoblotting analysis. Immunoblotting analysis was performed according to the procedures as previously described. 49 Membranes were visualized using an Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE, USA). Band density was normalized to β-actin. Antibodies against phospho-AMPK at Thr 172, phospho-ACC at Ser 79, AMPK α1, villin, DPPIV and CDX2 were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-E-cadherin antibody and anti-ZO-1 antibody were purchased from Life Technologies. Anti-sucrase-isomaltase antibody and anti-β-actin were purchased from DSHB (Iowa, IA, USA). IRDye 680 goat anti-mouse secondary antibody and IRDye 800CW goat anti-rabbit secondary antibody were purchased from Li-Cor Biosciences (Lincoln, NE, USA).
In vitro barrier function assessment. Twelve-well plate Millicells (0.4 μm, Millipore Corporation) were used for transepithelial electrical resistance (TEER) assays as described previously. 50 Briefly, 0.5 ml Caco-2 cells at the density of 4 × 10 5 cells/ml were seeded in the apical chamber that bathed in the basal chamber with 1.0 ml DMEM complete medium for 21 days. Voltage was measured daily using EVOM (WPI, Sarasota, FL, USA), which was multiplied by the area of filter (1.12 cm 2 ) to obtain the TEER in Ohm cm 2 . DMEM complete medium in apical and basal chamber was refreshed every day.
The permeability of FITC-dextran (Sigma) across the Caco-2 cell monolayer was measured as previously described with modifications. 51 At 21 days, 1.0 mg/ml FITCdextran was added on the apical side of monolayers after being washed twice with PBS. One milliliter sample in the basal chamber was taken at 30, 60, 90, 120, 180 and 240 min, respectively, and 1.0 ml pre-warmed fresh medium was added after each sampling to replenish basal medium. The fluorescence emission at 520 nm was measured with excitation at 490 nm using Synergy H1 microplate reader.
Immunohistochemistry and histopathology. Caco-2 cells were fixed in ice-cold methanol for 10 min, blocked in 5% goat serum at room temperature for 1 h, and incubated with anti-ZO-1 (1:200) or anti-CDX2 (1:200) antibody overnight at 4°C. Stained cells were then incubated with fluorescent secondary antibody (1:1000) at room temperature for 1 h. Goat anti-rabbit Alexa Fluor 488 and goat anti-mouse Alexa Fluor 555 were purchased from Cell Signaling Technology. Fluorescence was examined using EVOS FL fluorescence microscope (Life Technologies) as previously described. 52 Cryosections of mouse jejunum tissue were blocked with 5% goat serum for 1 h, incubated overnight with anti-BrdU antibody, anti-CDX2 antibody, anti-phospho-AMPK at Thr 172 or anti-ZO-1 at 4°C. An ABC kit (Vector Laboratories, Burlingame, CA, USA) and DAB substrates (Vector Laboratories) were used for BrdU, followed by hematoxylin counterstaining. Immunoreactive sites were visualized by using either fluorescence microscope or Leica DM2000 LED light microscope (Wetzlar, Germany). The pathology was scored in a blinded manner including severity of inflammation, depth of injury and crypt damage by hematoxylin and eosin stain (H&E stain) as previously reported. 53 The severity of inflammation was scored as 0, 1, 2, 3 when the inflammation is none, slight, moderate and severe, respectively. The depth of injury was scored as 0, 1, 2, 3 when the injury was none, at mucosal, at mucosal and submucosal region, and at transmural region, respectively. The crypt damage was scored as 0, 1, 2, 3, 4 when the damage was none, about 1/3 crypt, about 2/3 crypt, about whole crypt and inducing complete loss of crypt, respectively.
Calcium switch assay. The analysis was conducted as previously described with calcium-free DMEM. 54 Briefly, Caco-2 cells were seeded onto 12-well plates at 2 × 10 5 cells per well and grown for 4 days, rinsed with PBS and cultured with calcium-free DMEM for 16 h before being switched back to regular DMEM with calcium. Cells were fixed in ice-cold methanol for 18 h before calcium switch (−18 h) and various time points (0, 4, 8, 16 and 24 h) after restoring Ca 2+ . Cells were then processed for routine ZO-1 immunofluorescent staining.
Quantitative reverse-transcriptase (RT)-PCR and qPCR. Total RNA was extracted from cells using TRIzol (Sigma). cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). qPCRs were performed using SYBR Green supermixture (Bio-Rad) on CFX96 RT-PCR detection system (Bio-Rad). The primers were designed cross two exons to prevent amplification of genomic DNA. Primer sequences and their respective PCR fragment lengths were as follows: CDX2 (122 bp): 5′-CTCGGCAGCCAAGTGAAAACCA-3′, and 5′-GCTTTCCTCC GGATGGTGATGTA-3′; qPCR quantification of CDX2 promoter fragments from chromatin immunoprecipitation (ChIP) for H3K4me3 and H3K27me3 was conducted using CDX2-ChIP (human) (268 bp): forward 5′-GTGGGAGGAAAGAAGGA AGAAAGG-3′, and reverse 5′-GTACATGCTCACGTCCTTGTCCAG-3′; qPCR quantification of CDX2 promoter fragments from ChIP for EZH2 and LSD1 was conducted using CDX2-ChIP (human)(179 bp): forward 5′-TGCGCCTCGACG TCTCCAAC-3′, and reverse 5′-CCTCCCTTTCTTCCTTCTTTCCTCC-3′. qPCR quantification of mouse CDX2 promoter fragments from ChIP for H3K4me3, H3K27me3, EZH2 and LSD1 was conducted using CDX2-ChIP (mouse) (270 bp): 5′-GGTGGTGGTGGGGACTGTGTG-3′, and reverse 5′-TGCTCCGTCGGCTCCT TGC-3′. β-actin was used as an internal control as previously reported. 55 Chromatin immunoprecipitation. Chromatin immunoprecipitation was performed as previously described. 56 Briefly, Caco-2 cells were seeded onto 12-well plates at 2 × 10 5 cells per well for 4 days, cross-linked with 1% formaldehyde for 10 min at room temperature and quenched with 125 mM glycine. After centrifuge, the pellet was lysed in ice-cold lysis buffer with protease inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA, USA), sonicated to break up DNA into 500-800 bp fragments. DNA-protein complex was precleaned with ChIP-grade protein G (Thermo Fisher Scientific), then incubated with an antibody against H3K4me3 (Cell Signaling Technology), H3K27me3 (Cell Signaling Technology), EZH2 (Cell Signaling Technology), LSD1 (Cell Signaling Technology) or normal rabbit IgG (Cell Signaling Technology) overnight at 4°C. The complex was pulled down with protein G, treated with RNase A (Thermo Fisher Scientific) and proteinase K (Zymo research, Irvine, CA, USA). DNA was purified with ChIP DNA clean and concentrator kit (Zymo Research), and used as templates for qPCR. Relative enrichment of detected proteins was normalized to input DNA using the ΔΔ-Ct method.
Transmission electron microscopy. TEM was performed per previous published method. 57 Briefly, jejunum segments were fixed in McDowell and Trump fixative (VWR, Radnor, PA, USA), rinsed in 0.1 M cacodylate-0.1 M sucrose buffer for En Bloc staining, followed by dehydration. Tissues were infiltrated and embedded in Spurr's low viscosity resin, followed by polymerization for 8 h at 70°C. Semithin sections were cut using glass knives, and examined under FEI Technai G2 20 Twin TEM (Hillsboro, OR, USA).
Statistical analysis. Statistical analyses were conducted as previously described. 58 For cell related studies, at least three independent experiments were carried out. For animal studies, each animal was considered as an experimental unit. Data are presented as means ± S.E.M. Statistical analysis was performed using Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). Differences between means were determined using Student's t-test followed by Duncan's multiple test when appropriate. P ⩽ 0.05 was considered to be statistically significant.
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